International: Southeast News

International Southeast News and information curated occasionally for international trade sourcing, training, assistance for global exporting and more



Posted September 16, 2021


MEMPHIS, Tenn., Aug. 29, 2021 /PRNewswire/ -- Innovative US based biotech company Triad Life Sciences, Inc (Triad or the Company), is pleased to announce the completion of a successful A$25 million funding round which saw strong support from major Australian institutional investors. The convertible note placement was led by Cannacord Genuity, with funds raised supporting Triad's US sales force expansion plans, R&D activities, and general working capital needs. The Company now plans to move forward with a listing on the Australian Securities Exchange (ASX) in the coming months.

Triad is now bringing to market its ground-breaking FDA-cleared technology platform engineered to address unmet clinical needs in treating complex surgical wounds, chronic stalled wounds, and burns. Triad's proprietary, patent-pending technology provides innovative treatment solutions derived from a naturally occurring extracellular matrix (ECM) material. The Company's InnovaMatrix™ Advanced Care Placental ECM offers a unique, unparalleled solution to challenges with using human cell and tissue products while also providing the reliability, reproducibility, and safety profile of a medical device.


buttonsubscribe   buttonsignin



Only members have access to curated Southeast news for technology, fintech, growth and exporting specifically for the 27 major cities in the regional states of Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee. It’s about the executives and the decisions that result in the business activities that make the American Southeast the strong economic powerhouse – even stronger. Subscribe now!




Terms of Service Privacy Policy Site Map
Copyright @ 2021 Globalspeak, All Rights Reserved